- Home
- AIRT vs ANL Comparison
AIRT vs ANL Comparison
Compare AIRT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIRT | ANL |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 350.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AIRT | ANL |
|---|---|---|
| Price | $20.51 | $8.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 2.0K | ★ 446.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.56 | $0.88 |
| 52 Week High | $26.70 | $12.09 |
Technical Indicators
Market Signals| Indicator | AIRT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 50.65 |
| Support Level | $19.40 | $1.36 |
| Resistance Level | $20.97 | $12.09 |
| Average True Range (ATR) | 0.54 | 0.83 |
| MACD | -0.44 | -0.50 |
| Stochastic Oscillator | 5.64 | 27.89 |
Price Performance
Historical ComparisonAbout AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.